Sarepta Therapeutics (SRPT) Tops Q1 EPS by 75c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of $0.73, $0.75 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $413.5 million versus the consensus estimate of $379.15 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
• B.Riley on Nayax (NYAX): 'Sell-Off Overshoots the Story'